Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

PathMaker Neurosystems initiates European operations in Paris, France

PathMaker Neurosystems has established European operations at the iPEPS-ICM bioincubator at the Brain and Spine Institute in Pitié-Salpêtrière Hospital in Paris, France.

The Brain and Spine Institute is an international center of excellence focused on research into neurological diseases, employing over 600 physicians and scientific researchers who are among the most highly regarded in the world.

The iPEPS-ICM bioincubator was established to accelerate the transformation of breakthrough ideas in the neuroscience field into innovative products by furnishing an environment ideal for the development and commercialization of novel technologies.

ICM Research and Technology Development head Alexis Genin said: "We are pleased to welcome PathMaker Neurosystems, an innovative company active in the field of neuromodulation that is collaborating with researchers from our institute.

"We look forward to working with PathMaker as they advance their novel tsDCS-based technology into clinical trials."

PathMaker president and chief executive officer Nader Yaghoubi said: "We are delighted to have been selected to join the iPEPS-ICM bioincubator.

"By establishing our European office and operations at France’s leading neurological research institution, we not only will be able to work closely with leading specialists and researchers, but will also be able to utilize core research facilities and the specialized Clinical Investigation Centre at ICM."

PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders.

tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our Company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders.

More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.